Polyneuron has obtained the orphan drug designation from the European Medicines Agency (EMA) for PN-1007 as a novel treatment for anti-MAG neuropathy. The EMA offers a range of incentives with the orphan designation, including free protocol assistance for SMEs, centralized authorization procedure, and extended market exclusivity. The grant of this designation is a key milestone for Polyneuron.